H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating

CG Oncology, Inc. (NASDAQ:CGON) is among the 10 Fastest Growing NASDAQ Stocks to Buy.

On February 27, 2026, H.C. Wainwright raised the firm’s price target on CG Oncology, Inc. (NASDAQ:CGON) to $80 from $75 and maintained a Buy rating on the shares. The analyst said the company is advancing toward a biologics application submission for cretostimogene in high-risk non-muscle invasive bladder cancer, supported by strong durability and safety data, while also expanding into earlier treatment settings. The firm added that the Phase 3 PIVOT-006 trial in intermediate-risk NMIBC represents a key 2026 catalyst that could significantly broaden the company’s clinical and commercial opportunity.

On February 27, 2026, CG Oncology, Inc. (NASDAQ:CGON) reported FY25 EPS of ($2.08), compared with consensus estimates of (58c). The company reported revenue of $4.04M, above the $515,180 consensus estimate. Chairman and CEO Arthur Kuan said the company expects to report topline data from PIVOT-006 in the coming months, describing the study as “the first randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC.” Kuan added that the company believes it has the opportunity to establish a new standard in intermediate-risk NMIBC and highlighted cretostimogene’s “unique best-in-disease profile.” He also noted that results from CORE-008 Cohort CX in high-risk BCG-exposed patients evaluating cretostimogene in combination with gemcitabine are expected in the coming quarter.

CG Oncology, Inc. (NASDAQ:CGON) is a late-stage clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutics for patients with bladder cancer.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey on Google News.